Abstract
Background Repeated serosurveys in the same population provide more accurate estimates of the frequency of SARS-CoV-2 infection and more comparable data than notified cases. We aimed to estimate the incidence of SARS-CoV-2 infection, identify associated risk factors, and assess time trends in the ratio of serological/molecular diagnosis in a cohort of university workers.
Methods Participants had a serological rapid test for SARS-CoV-2 Immunoglobulins M and G, and completed a questionnaire, in May-July 2020 (n=3628) and November 2020–January 2021 (n=2661); 1960 participated in both evaluations and provided data to compute the incidence proportion and the incident rate. Crude and adjusted incidence rate ratios (aIRR) and 95% confidence intervals (CI) were computed using generalised linear models with Poisson regression.
Results The incidence rate was 1.8/100 person-month (95%CI 1.6-2.1), and the 6 months’ cumulative incidence was 10.7%. The serological/molecular diagnosis ratio was 10:1 in the first evaluation and 3:1 in the second. Considering newly identified seropositive cases at the first (n=69) and second evaluation (n=202), 29.0% and 9.4% never reported symptoms, respectively, 14.5% and 33.3% reported contact with a confirmed case and 82.6%, and 46.0% never had a molecular test. Males (aIRR: 0.59; 95%CI: 0.42-0.83) and “high-skilled white-collar” workers (aIRR: 0.73, 95%CI: 0.52-1.02) had lower incidence of infection.
Conclusion University workers presented a high SARS-CoV-2 incidence while restrictive measures were in place. The time decrease in the proportion of undiagnosed cases reflected the increased access to testing, but opportunities continued to be missed, even in the presence of COVID-19 like symptoms.
What is already known on this subject
The median ratio of seroprevalence to the corresponding cumulative incidence is 18, however, there is great variability between studies.
Seroprevalence studies are essential to estimate the true burden of the infection.
Few cohort studies focused on essential non-healthcare workers, such as university workers.
What this study adds
This longitudinal seroprevalence study among university workers found a SARS-CoV-2-specific IgM or IgG incidence rate of 1.8/100 person-month, and a 6 months’ cumulative incidence of 10.7%.
The undiagnosed fraction was 3:1 in the second evaluation, representing a decrease from a 10:1 in the first evaluation in the same population showing that a gap to test-trace-isolate remained in this highly educated working population.
Seropositive participants were mostly pauci- or symptomatic with no known contact with a COVID-19 confirmed case; “high-skilled white-collar” workers were at lower risk of being an incident seropositive case.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the University of Porto and supported by national funds of Fundacao para a Ciencia e Tecnologia (FCT), under the scope of the project UIDB/04750/2020 - Research Unit of Epidemiology-Institute of Public Health of the University of Porto (EPIUnit). JPC is the recipient of a Ph.D. grant (DFA/BD/8562/2020) co-funded by the national funds of FCT and the Fundo Social Europeu (FSE). Authors declare no conflicts of interest.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the ethics committee of the Institute of Public Health of the University of Porto (ID 20154).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The dataset analysed during the current study is available on reasonable request to the study coordinator (PM, paula.meireles{at}ispup.up.pt).
